AI’s Role in Orthopedics: Advancements and Challenges

By Sumona Bose

January 8, 2024

Introduction

Artificial intelligence (AI) has rapidly evolved from a theoretical concept to a practical application with the help of affordable computational power and the availability of large data sets. In the healthcare field, AI has the potential to invigorate orthopedic treatment by addressing specific challenges such as image recognition, preoperative risk assessment, clinical decision-making, and analysis of massive data sets. A recent systematic review by Cabitza et al. highlighted the increasing number of initiatives that leverage AI to tackle orthopedic-specific problems. The review found that spine pathology, osteoarthritis (OA) detection and prediction, and imaging of bone and cartilage were the most studied topics. Machine learning (ML) techniques, particularly deep learning (DL) and support vector machines (SVMs), were the most frequently applied algorithms. Medical imaging data emerged as the most commonly used input source. This article will explore AI’s role in Orthopedics.

Discussing Challenges in AI Research

While the potential of AI in orthopedics is promising, there are challenges that need to be addressed. One of the main concerns is the accusation that AI in medicine provides no advantage over traditional statistics. However, this claim is unfounded as AI has proven to be effective in various medical applications. It is important to view traditional statistics and ML as lying on a spectrum rather than as distinct techniques.

To successfully implement AI in orthopedics, certain prerequisites need to be met. These include big accurate data sets, powerful computers, cloud computing, and open-source algorithmic development. However, there are additional challenges associated with AI research, such as privacy issues and biasing. If the data used to train AI models are biased, it can lead to systematic analytical mistakes. For example, if the training data predominantly consists of medical records of white men, the AI may make less accurate predictions for women, ethnic minorities, or other underrepresented groups.

Furthermore, AI lacks traits that are uniquely human, such as morality and intuition, making it prone to absurd mistakes. Adversarial attacks, which intentionally bias or force AI models to make errors, pose a significant threat to patient care and safety. These attacks can impact medical diagnosis, decision support, insurance claims, drug and device approvals, and clinical trials. AI’s role in Orthopedics highlight an important area in the medical industry where practical knowledge will meet theoretical insights.

Conclusion

Addressing these challenges requires careful consideration. Regulating AI too early may stifle innovation and result in inaccurate threat-based models and unwieldy regulatory structures. However, delaying regulation may leave healthcare systems vulnerable to adversarial attacks.

Reference url

Recent Posts

Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...
Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promising New Data
Johnson & Johnson has announced promising new data across multiple solid tumor types, which will be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, and the company describes this as "a new era" in their solid tumor research. The press release highlights ...